Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
IPO Year:
Exchange: AMEX
Website: navidea.com
| Date | Price Target | Rating | Analyst |
|---|
EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
S-8 POS - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
POS AM - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
POS AM - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Joshua ("Josh") Wilson to its Board of Directors, effective September 30, 2022, with a term ending concurrently with the Company's 2024 annual stockholders' meeting. Mr. Wilson is a seasoned banking and finance executive with more than 23 years of financial services and family office experience. During his career, Mr. Wilson focused his efforts on raising capital and streamlining company operations for profit and non-profit entities, raising more than $500 million. Currently, Mr. Wilso
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the resignation of Jed A. Latkin as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of the Company, and as a member of the Board of Directors of the Company, effective October 24, 2021. Mr. Latkin and the Company are discussing the terms of a severance agreement pursuant to his employment contract. An Office of the CEO including three members of the Company's Board of Directors has been established to lead the Company on an interim basis while the next Chief Executive Officer
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Thomas Forest Farb-Horch and Agnieszka Winkler to its Board of Directors, effective October 7, 2021, each with a three-year term ending concurrently with the Company's 2024 annual stockholders' meeting. Thomas Forest Farb-Horch has over three decades of experience as an investor in and senior executive of numerous life science and information technology companies both in the U.S. and internationally. Mr. Farb has served as the Chief Executive Officer, President, co-founder and director
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Michel Mikhail, Ph.D. as Chief Regulatory Officer of Navidea, effective October 1, 2021. Dr. Mikhail has more than 30 years of experience in the pharmaceutical industry and a track record of achievement in R&D and international regulatory affairs at large multinational research-based pharmaceutical companies. Prior to joining Navidea, Dr. Mikhail worked in global regulatory consulting for various pharmaceutical and biotech companies from January 2016 through September 2021. Before acti
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment Malcolm G. Witter to its Board of Directors. Mr. Witter brings decades of financial and corporate governance experience to the board. He currently serves as a corporate development leader for USI Insurance Services (“USI”) and is responsible for acquiring independent insurance agencies. Prior to USI, Mr. Witter held roles at multiple financial institutions including Bear Stearns, EF Hutton, and Dean Witter. Mr. Witter received his MBA fro
Navidea Biopharmaceuticals, Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company's pivotal NAV3-33 clinical trial titled "Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)" (ClinicalTrials.gov Identifier: NCT05246280) the "RA Trial." The purpose of the exploratory analysis was to optimize th
Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024 Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company's certificate of incorporation to allow stockholders to act by written consent, and (ii) an amendment to the Company's certificate of incorporation to implement a reverse stock
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a Form 15 with the Securities and Exchange Commission (the "SEC") to deregister its common stock, preferred stock purchase rights and Series K preferred stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to suspend its reporting oblig
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation. Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the Company and Capital Royalty Partners II, L.P. and other related entities (collectively, "CRG") have entered into a binding settlement agreement and mutual release settling all ongoing litigation between the parties. CRG Settlement Agreement and Mutual Release Aligns with Company's Approach Navidea and CRG have been engaged in ongoi
The Company announced today that the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the NYSE American LLC upheld the NYSE Regulation staff's previously announced determination to initiate delisting proceedings with respect to the Company's common stock. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Listings Qualifications Panel (the "Panel") of the Committee for Review of the Board of Directors of the NYSE American LLC (the "Com
Following the Company's Fix, Fund, Propel approach, Navidea formally submitted a request for an oral hearing with New York Stock Exchange American (NYSE American) Hearing Panel to appeal potential delisting of its stock from the NYSE American. Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it has formally submitted a request for an oral hearing with NYSE American Hearing Panel to appeal potential delisting of its stock from the New York Stock Exchange (NYSE American), while also continuing its Fix, Fund, Propel approach. "We are taking the prudent
Following the Company's Fix, Fund, Propel approach, Navidea continues forward-focus to advance innovative technology to market while intending to appeal the potential delisting of its stock from the New York Stock Exchange (NYSE). Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its continued and steadfast focus on moving the Company forward and leveraging its Fix Fund Propel approach while also intending to appeal potential delisting from the NYSE American Exchange. "Although the traditional exchange has been a part of Navidea's history and may be
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea Biopharmaceuticals, Inc. (the "Company") — ticker symbol NAVB —from the Exchange. The Company's Board of Directors has determined to appeal the Exchange's determination to commence delisting proceedings. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of
Following the Company's Fix, Fund, Propel approach, Mr. Dais's hire strengthens financial expertise, leadership, and oversight, along with continuing Navidea's focus on advancing innovative technology to market Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the hiring of Craig A. Dais, CPA in the position of Chief Financial Officer (CFO), reporting directly to the Company's Chief Medical Officer. Mr. Dais's hiring aligns with the Company's stated objectives and its Fix, Fund, Propel approach to advancing innovative technology to market. Financial
In line with the Company's Fix, Fund, Propel approach, Dana J Moss, JD joins Navidea's Board, adding depth in legal advice, strategic business, life sciences and technology in support of stated strategy to advance innovative technology to market. Separately, Amit Bhalla steps down from Board. Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced Dana J Moss, JD has joined the Company's Board of Directors, adding depth in legal advice, strategic business, life sciences and technology in line with Navidea's stated objectives and its Fix, Fund, Propel approac
4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
3 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
3 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
3 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series K Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 27, 2023. The shares of Series K Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on June 27, 2023. The outstanding shares of Series K Preferred Stock will vote together with the outstanding shares of the Company's
The company introduces Fix, Fund, Propel approach to further focus on strategic objectives; will publish financial and corporate development highlights via press release in lieu of conference call and webcast for Q1 2023 results. Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the introduction of a Fix, Fund, Propel approach to driving the Company's strategy forward; The Company will issue a press release detailing financial highlights and corporate developments in lieu of hosting conference call and webcast for the first quarter ended March 31st, 20
Conference Call to be held Tuesday, March 21, 2023 at 5:00 pm (EDT) Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the three-month and twelve-month periods ended December 31, 2022. Fourth Quarter 2022 Highlights and Subsequent Events Continued enrollment into the Company's NAV3-33 Phase 3 trial in rheumatoid arthritis ("RA") titled "Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis." The Company announced enrollme
Conference Call to be Held on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, March 21, 2023 at 5:00 p.m. (EDT) to discuss corporate developments and financial results for the fourth quarter and full year ended December 31, 2022. Dr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on recent developments and clinical pr
Conference Call to be held Tuesday, November 15, 2022 at 5:00 pm (EST) Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the three-month and nine-month periods ended September 30, 2022. Third Quarter 2022 Highlights and Subsequent Events Continued enrollment into the Company's NAV3-33 Phase 3 trial in rheumatoid arthritis ("RA") titled "Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis." Announced the opening of ni
Conference Call to be Held on Tuesday, November 15, 2022 at 5:00 p.m. (EST) Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, November 15, 2022 at 5:00 p.m. (EST) to discuss corporate developments and financial results for the third quarter ended September 30, 2022. Dr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on recent developments and clinical progress.
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the preliminary results of its rights offering which expired at 5:00 P.M. Eastern Time on August 24, 2022. The Company estimates that the rights offering will result in total subscriptions of approximately $14.2 million. Navidea expects to receive from the rights offering aggregate gross cash proceeds of approximately $6.1 million (excluding additional proceeds of up to $15.8 million from the exercise of warrants issued in the rights offering, if any such exercises occur), and the exchange and cancellatio
Conference Call to be Scheduled at a Later Date Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2022. Second Quarter 2022 Highlights and Subsequent Events Continued enrollment into the Company's NAV3-33 Phase 3 trial in rheumatoid arthritis ("RA") titled "Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis." Enrollment is ongoing across the three curre
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the subscription period for the previously announced rights offering has commenced. If exercising subscription rights through a broker, dealer, bank or other nominee, rights holders should promptly contact their nominee and submit subscription documents and payment for the units subscribed for in accordance with the instructions and within the time period provided by such nominee. The broker, dealer, bank or other nominee may establish a deadline before August 17, 2022, by which instructions to exerc
Conference Call to be held Thursday, May 12, 2022 at 5:00 pm (EDT) Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter for the period ended March 31, 2022. First Quarter 2022 Highlights and Subsequent Events Continued enrollment into the Company's NAV3-33 Phase 3 trial in rheumatoid arthritis ("RA") titled "Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis." Announced positive preliminary results f
SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13G/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13G/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13G - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
SC 13D/A - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Subject)
Gainers Femasys Inc. (NASDAQ:FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment. Tharimmune Inc (NASDAQ:THAR) shares rose 101.4% to $0.4450 in pre-market trading after falling around 5% on Monday. Infobird Co., Ltd (NASDAQ:IFBD) shares gained 31.1% to $0.1709 in pre-market trading. Infobird recently announced receipt of delinquency notification letter from the Nasdaq. Avalo Therapeutics, Inc. (NASDAQ:AVTX) gained 19.3% to $0.1945 in pre-market trading after jumping over 36% on Monday. The company recently announced the sale of its assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and
Gainers Connexa Sports Technologies Inc. (NASDAQ:CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday. Avinger, Inc. (NASDAQ:AVGR) gained 63.9% to $9.95, adding to outsized gains from Monday. On Monday, Avinger shares soared 46.8% after the company announced the commercial launch of its Tigereye ST image-guided CTO crossing device. Sezzle Inc. (NASDAQ:SEZL) shares climbed 46.6% to $18.95. PHAXIAM Therapeutics S.A. (NASDAQ:PHXM) rose 30% to $5.17. Elutia Inc. (NASDAQ:ELUT) shares gained 29.1% to $1.6006 after the company announced the sale of its Orthobiologics business unit to Berkeley Biologics LLC. Elutia announced $26 million private placement of 7,355,869 shares of co
Gainers Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares increased by 172.7% to $0.01 during Tuesday's pre-market session. Avinger (NASDAQ:AVGR) shares rose 47.61% to $8.96. The company's market cap stands at $6.4 million. Navidea Biopharmaceutical (AMEX:NAVB) shares increased by 22.75% to $0.11. The market value of their outstanding shares is at $11.3 million. Elutia (NASDAQ:ELUT) stock increased by 22.58% to $1.52. The company's market cap stands at $24.6 million. ABVC BioPharma (NASDAQ:ABVC) stock rose 19.81% to $1.27. The market value of their outstanding shares is at $5.0 million. Akili (NASDAQ:AKLI) stock increased by 19.69% to $0.79. The market value of their outstandi
Gainers First Wave BioPharma (NASDAQ:FWBI) stock moved upwards by 108.7% to $0.91 during Thursday's pre-market session. The market value of their outstanding shares is at $6.4 million. Avalo Therapeutics (NASDAQ:AVTX) stock moved upwards by 34.1% to $0.3. The market value of their outstanding shares is at $6.0 million. TransCode Therapeutics (NASDAQ:RNAZ) shares rose 22.22% to $1.1. The company's market cap stands at $2.2 million. Navidea Biopharmaceutical (AMEX:NAVB) shares moved upwards by 20.6% to $0.14. The market value of their outstanding shares is at $14.0 million. Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) stock rose 14.94% to $0.01. Evoke Pharma (NASDAQ:EVOK) shares i
Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of $0.10/less for 10 consecutive trading days. ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) gained 63.5% to $0.2101. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) rose 31.8% to $20.15 after the company announced that alignment has been reached with the FDA on the global Phase 2 pivotal trial of RP-A501 for Danon Disease. Connexa Sports Technologies Inc. (NASDAQ:CNXA) gained 22.2% to $0.1090. Axcella Health Inc. (NASDAQ:AXLA) shares jumped 19.3% to $1.36 after jumping more than 59% on Tuesday. Alset Capita
Gainers PhenomeX (NASDAQ:CELL) shares increased by 136.4% to $0.95 during Thursday's regular session. As of 13:31 EST, PhenomeX's stock is trading at a volume of 19.6 million, which is 2758.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $93.9 million. As per the press release, Q2 earnings came out 3 days ago. Tivic Health Systems (NASDAQ:TIVC) shares increased by 59.98% to $0.11. As of 13:31 EST, this security is trading at a volume of 429.4 million shares, making up 1776.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.7 million. As per the news, the Q2 earnings re
Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock increased by 68.6% to $0.2 during Wednesday's regular session. Trading volume for this security as of 13:31 EST is 346.2 million, which is 3787.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $29.0 million. Tivic Health Systems (NASDAQ:TIVC) stock increased by 59.13% to $0.06. As of 13:31 EST, this security is trading at a volume of 226.3 million shares, making up 1191.2% of its average full-day volume over the last 100 days. The company's market cap stands at $8.6 million. The company's, Q2 earnings came out 2 days ago. Navidea Biopharmaceutical (AMEX:NAVB) stock increased by
Gainers Yellow Corporation (NASDAQ:YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report. FOXO Technologies Inc. (NYSE:FOXO) rose 64.7% to $0.2232. Bruush Oral Care Inc. (NASDAQ:BRSH) gained 48% to $0.1979 after the company announced a 1-for-25 reverse stock split. Archer Aviation Inc. (NASDAQ:ACHR) shares climbed 41.8% to $6.78 after the company entered into contracts with the US Air Force with a total value of up to $142 million. Tupperware Brands Corporation (NYSE:TUP) gained 39.6% to $4.2999 amid possible short squeeze interest. Mallinckrodt plc (NYSE:MNK) jumped 39% to $1.51 on continued volatility followi